few weeks ago, a group of Democrats in both houses of Congress introduced the Improving Access to Affordable Prescription Drugs Act, a 129-page bill designed to lower drug prices while increasing innovation and cracking down on pharmaceutical company abuses (my thoughts on the bill are here).

There’s one provision that hasn’t gotten enough attention: the creation of a prize fund for new antibiotics.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Interesting article, thanks. With regard to the two points you highlight at the end, conditioning the prize on (1) making the product available at a low price, and (2) waiving IPRs (and other forms of exclusivity), readers may wonder why the second is necessary if the first is in effect. That is, one might ask, “if the winner of the prize can’t set a high price, why should I care any more if she still has a patent?” It would make this essay more useful if you were to explain that too. (To be clear, I think there’s a good answer to the question, I just wish it were included here, as it may not be obvious to many readers).

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy